5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
复制标题
5-氟尿嘧啶、甲基-CCNU 以及联合或不联合睾内酯的放疗治疗外分泌胰腺局限性腺癌：西南肿瘤小组研究。
DOI：
10.1002/1097-0142(19801001)46:7
复制
发表时间：
1980
期刊：
影响因子：
6.2
通讯作者：
Moore,TN
中科院分区：
文献类型：
--
作者：
McCracken,JD;Ray,P;Heilbrun,LK;Vaitkevicius,VK;Saiki,JH;Rivkin,SE;Rossof,AH;Moore,TN
自 1975 年 8 月以来，69 例局限性胰腺癌（肿瘤范围仅限于 15 cm × 15 cm 放疗端口）患者接受了方案 A，包括对肿瘤区域进行放疗（6,000 rad），同时采用甲基-CCNU 125 mg/m2 口服（每六周）和 5-氟尿嘧啶（400 mg/m2）静脉注射，每周进行联合化疗；或方案B，包含方案A并添加睾内酯，200mg，每天口服。目前，接受方案 A 的 38 名患者和接受方案 B 的 30 名患者目前可进行评估。方案 A 组的中位生存期为 38 周，方案 B 组的中位生存期为 30 周（P= 0.677），似乎不受添加睾内酯的影响。所有患者的中位生存时间为 38 周。良好的体能状态与较差的体能状态相比，确实与生存率的提高相关（46 周与 20 周，P= .008）。 15例患者生存时间超过52周，最长生存时间为160+周，其中3例已停止所有治疗。然而，大多数患者出现中度至重度血液毒性反应。 6 例中有 1 例与治疗相关的死亡和严重胃肠道出血。由于该方案的毒性反应，不应考虑采用类似的攻击性较小的方案。
Since August 1975, 69 patients with localized pancreatic carcinoma (extent of tumor confined to a 15 cm × 15 cm radiotherapy port) have received either Regimen A, comprising radiotherapy (6,000 rad) to the tumor area with simultaneous combination chemotherapy utilizing methyl‐CCNU, 125 mg/m2orally, every six weeks, and 5‐fluorouracil, 400 mg/m2intravenously, weekly; or Regimen B, comprising Regimen A with the addition of testolactone, 200 mg, orally every day. Thirty‐eight patients on Regimen A and 30 patients on Regimen B are currently evaluable. Median survival, which appeared not to be affected by the addition of testolactone, was 38 weeks for those on Regimen A and 30 weeks for those on Regimen B (P= 0.677). The median survival time for all patients was 38 weeks. Good performance status did correlate with improved survival vs. poor performance status (46 weeks vs. 20 weeks,P= .008). Fifteen patients have survived for more than 52 weeks, with the longest survival time being 160 + weeks, and in 3 cases all therapy has been discontinued. However, most patients experienced moderate to severe hematologic toxic reactions. There was one treatment‐related death and significant gastrointestinal bleeding developed in 6. Because of the toxic reactions of this program, it should not be considered in favor of similar less aggressive programs.